anti-SARS-CoV-2 spike protein CAR NK-cell therapy (Rutgers University/Ohio State University/Temple University Lewis Katz School of Medicine)

N/A

Report date: 2025/01/26 17:59:40

Base Information

Drug Nameanti-SARS-CoV-2 spike protein CAR NK-cell therapy (Rutgers University/Ohio State University/Temple University Lewis Katz School of Medicine)
Drug Alias NameS309-CAR-NK cellsS309-IL15-CAR-NK cells
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionInterleukin-15 receptors agonistsCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoproteinInterleukin-15 receptors
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRutgers University
China Registration ClassN/A

Develop Information

Active CompaniesLewis Katz School of MedicineThe Ohio State UniversityRutgers University
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A